The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Big-box retailers and Amazon are positioning themselves to capture a growing share of the direct-to-consumer GLP-1 market. For patients, this shift could mean lower prices and easier access, but also new tradeoffs around care quality and safety. Here's what you need to know before you buy.
Bathroom mini fridges are trending partly because of GLP-1 medications like Ozempic and Wegovy, which require refrigeration. This guide covers proper storage temperatures, what happens when medication gets too warm or too cold, and whether a dedicated fridge is actually worth the investment.
Indiana Governor Braun has announced that some Medicaid recipients in the state can access select GLP-1 medications. Here is what Indiana residents need to know about eligibility, covered drugs, and next steps for getting access.
Novo Nordisk has reported increased profits in Russia even after suspending Ozempic sales there. While this may seem like a distant business story, it raises real questions about global drug pricing, supply chains, and what patients in the U.S. can expect from one of the world's largest GLP-1 manufacturers.
Hanmi Pharmaceutical's efpeglenatide is emerging as a serious contender in the GLP-1 obesity drug market, targeting the same patients who currently use Wegovy and Mounjaro. Here's what the emerging data suggests, what questions remain, and how to think about your own treatment options as new competitors arrive.
Rosie O'Donnell recently opened up about her exact Mounjaro dosage and her surprisingly smooth experience with the medication. Her story raises important questions about tirzepatide dosing, side effect management, and what patients can realistically expect. Here's how to make sense of her experience alongside the clinical evidence.
A new Medicare program is poised to significantly expand access to GLP-1 medications like semaglutide and tirzepatide for older Americans. Here's what beneficiaries need to know about eligibility, potential savings, and how to navigate the changes with their doctor.
Millions of people qualify for GLP-1 medications on paper, but a growing number are hitting roadblocks when they try to actually get them. From insurance denials to pharmacy shortages and prior authorization battles, here is what is standing between patients and their prescriptions, and what you can do about it.
.avif)